JP2017530195A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017530195A5 JP2017530195A5 JP2017536991A JP2017536991A JP2017530195A5 JP 2017530195 A5 JP2017530195 A5 JP 2017530195A5 JP 2017536991 A JP2017536991 A JP 2017536991A JP 2017536991 A JP2017536991 A JP 2017536991A JP 2017530195 A5 JP2017530195 A5 JP 2017530195A5
- Authority
- JP
- Japan
- Prior art keywords
- rivastigmine
- formulation
- aqueous
- nasal
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020036966A JP7357571B2 (ja) | 2014-10-03 | 2020-03-04 | 神経学的及び神経変性疾患及び障害を処置するための鼻腔投与組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2014903944A AU2014903944A0 (en) | 2014-10-03 | Intranasal compositions for treatment of neurological and neurodegenerative diseases and disorders | |
| AU2014903944 | 2014-10-03 | ||
| PCT/AU2015/050591 WO2016049700A1 (en) | 2014-10-03 | 2015-09-30 | Intranasal compositions for treatment of neurological and neurodegenerative diseases and disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020036966A Division JP7357571B2 (ja) | 2014-10-03 | 2020-03-04 | 神経学的及び神経変性疾患及び障害を処置するための鼻腔投与組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017530195A JP2017530195A (ja) | 2017-10-12 |
| JP2017530195A5 true JP2017530195A5 (enExample) | 2018-11-08 |
Family
ID=55629161
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017536991A Pending JP2017530195A (ja) | 2014-10-03 | 2015-09-30 | 神経学的及び神経変性疾患及び障害を処置するための鼻腔投与組成物 |
| JP2020036966A Active JP7357571B2 (ja) | 2014-10-03 | 2020-03-04 | 神経学的及び神経変性疾患及び障害を処置するための鼻腔投与組成物 |
| JP2021171712A Pending JP2022003100A (ja) | 2014-10-03 | 2021-10-20 | 神経学的及び神経変性疾患及び障害を処置するための鼻腔投与組成物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020036966A Active JP7357571B2 (ja) | 2014-10-03 | 2020-03-04 | 神経学的及び神経変性疾患及び障害を処置するための鼻腔投与組成物 |
| JP2021171712A Pending JP2022003100A (ja) | 2014-10-03 | 2021-10-20 | 神経学的及び神経変性疾患及び障害を処置するための鼻腔投与組成物 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US10471040B2 (enExample) |
| EP (1) | EP3200828B1 (enExample) |
| JP (3) | JP2017530195A (enExample) |
| AU (1) | AU2015327762C1 (enExample) |
| CA (1) | CA2961936C (enExample) |
| DK (1) | DK3200828T3 (enExample) |
| ES (1) | ES2822562T3 (enExample) |
| HU (1) | HUE052441T2 (enExample) |
| PL (1) | PL3200828T3 (enExample) |
| PT (1) | PT3200828T (enExample) |
| SM (1) | SMT202000576T1 (enExample) |
| WO (1) | WO2016049700A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3200828T3 (pl) * | 2014-10-03 | 2021-01-25 | Lachesis Biosciences Limited | Kompozycje donosowe do leczenia chorób i zaburzeń neurologicznych i neurodegeneracyjnych |
| SI3698791T1 (sl) * | 2017-02-02 | 2024-05-31 | Otolanum Ag | Intranazalni sestavek, ki vsebuje betahistin |
| US20230172895A1 (en) * | 2020-06-25 | 2023-06-08 | Lachesis Biosciences Limited | Methods of treating or preventing organophosphorus poisoning |
| CN116322647A (zh) * | 2020-08-07 | 2023-06-23 | 科学和工业研究委员会 | 用于治疗急性呼吸窘迫综合征的微乳剂药物递送体系 |
| GB2614167A (en) * | 2020-10-01 | 2023-06-28 | Lyra Therapeutics Inc | Osmotic drug delivery implants |
| CN115919767B (zh) * | 2022-10-13 | 2023-08-11 | 暨南大学 | 卡巴拉汀鼻喷雾剂及其制备方法 |
| CN119523898A (zh) * | 2024-12-02 | 2025-02-28 | 肇庆学院 | 多靶点药物的经鼻给药制剂及其应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR5733M (enExample) | 1966-09-27 | 1968-01-22 | ||
| US4806543A (en) | 1986-11-25 | 1989-02-21 | Board Of Trustees Of The Leland Stanford Junior University | Method and compositions for reducing neurotoxic injury |
| FR2722989B1 (fr) | 1994-07-29 | 1997-05-30 | Synthelabo | Utilisation de l'ifenprodil et de ses enantiomeres pour la preparation de medicaments utiles dans le traitement des neuropathies peripheriques et des maladies neurodegeneratives centrales |
| US6558560B2 (en) * | 2001-07-27 | 2003-05-06 | Hewlett-Packard Company | Method for the fabrication of electrical contacts |
| WO2004034963A2 (en) * | 2002-05-17 | 2004-04-29 | Eisai Co., Ltd. | Methods and compositions using cholinesterase inhibitors |
| US20040254146A1 (en) * | 2002-05-21 | 2004-12-16 | Nastech Pharmaceutical Company Inc. | Carboxylate salts of galantamine and their pharmaceutical use |
| US20030225031A1 (en) * | 2002-05-21 | 2003-12-04 | Quay Steven C. | Administration of acetylcholinesterase inhibitors to the cerebral spinal fluid |
| EP1811979B1 (en) * | 2004-09-27 | 2008-11-05 | Sigmoid Pharma Limited | Microcapsules comprising a methylxanthine and a corticosteroid |
| US8187570B1 (en) * | 2005-01-04 | 2012-05-29 | Gp Medical, Inc. | Nanoparticles for protein drug delivery |
| BRPI0607017B8 (pt) * | 2005-04-06 | 2021-05-25 | Adamas Pharmaceuticals Inc | composição farmacêutica compreendendo memantina e donezepil, e seu uso para o tratamento de condições relacionadas ao snc |
| US8911751B2 (en) * | 2005-10-11 | 2014-12-16 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Compositions for nasal delivery |
| WO2007043057A2 (en) * | 2005-10-11 | 2007-04-19 | Yissum, Research Development Company Of The Hebrew University Of Jerusalem | Compositions for nasal delivery |
| CA2641392A1 (en) * | 2006-02-03 | 2007-08-16 | Avanir Pharmaceuticals | Pharmaceutical compositions for treating depression, anxiety and neurodegenerative disorders |
| EP1981475A2 (en) * | 2006-02-09 | 2008-10-22 | Schering Corporation | Pharmaceutical formulations |
| KR20100031608A (ko) * | 2007-06-26 | 2010-03-23 | 와카모토 세이야꾸 가부시끼가이샤 | 수성 조성물 |
| FR2931677B1 (fr) * | 2008-06-02 | 2010-08-20 | Sanofi Aventis | Association d'un agoniste partiel des recepteurs nicotiniques et d'un inhibiteur d'acetylcholinesterase, composition la contenant et son utilisation dans le traitement des troubles cognitifs |
| MY165234A (en) | 2010-05-17 | 2018-03-14 | Forum Pharmaceuticals Inc | A crystalline form of (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate |
| US8673338B2 (en) * | 2011-07-29 | 2014-03-18 | Massachusetts Eye And Ear Infirmary | Methods of delivering pharmaceutical agents |
| PL3200828T3 (pl) * | 2014-10-03 | 2021-01-25 | Lachesis Biosciences Limited | Kompozycje donosowe do leczenia chorób i zaburzeń neurologicznych i neurodegeneracyjnych |
-
2015
- 2015-09-30 PL PL15848100T patent/PL3200828T3/pl unknown
- 2015-09-30 HU HUE15848100A patent/HUE052441T2/hu unknown
- 2015-09-30 CA CA2961936A patent/CA2961936C/en active Active
- 2015-09-30 AU AU2015327762A patent/AU2015327762C1/en active Active
- 2015-09-30 JP JP2017536991A patent/JP2017530195A/ja active Pending
- 2015-09-30 PT PT158481002T patent/PT3200828T/pt unknown
- 2015-09-30 DK DK15848100.2T patent/DK3200828T3/da active
- 2015-09-30 WO PCT/AU2015/050591 patent/WO2016049700A1/en not_active Ceased
- 2015-09-30 ES ES15848100T patent/ES2822562T3/es active Active
- 2015-09-30 EP EP15848100.2A patent/EP3200828B1/en active Active
- 2015-09-30 US US15/516,233 patent/US10471040B2/en active Active
- 2015-09-30 SM SM20200576T patent/SMT202000576T1/it unknown
-
2019
- 2019-09-13 US US16/569,986 patent/US10933045B2/en active Active
-
2020
- 2020-03-04 JP JP2020036966A patent/JP7357571B2/ja active Active
-
2021
- 2021-01-27 US US17/160,009 patent/US11911360B2/en active Active
- 2021-10-20 JP JP2021171712A patent/JP2022003100A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017530195A5 (enExample) | ||
| JP6657454B2 (ja) | ブプレノルフィンの乱用抵抗性粘膜付着性送達デバイス | |
| US11872314B2 (en) | Pharmaceutical compositions | |
| US20210308040A1 (en) | Ketamine oral transmucosal delivery system | |
| JP2018517676A5 (enExample) | ||
| TW201016209A (en) | Intranasal compositions, dosage forms and methods of treatments | |
| WO2013081565A1 (en) | Pharmaceutical compositions comprising roflumilast and terbutaline | |
| JP5775970B2 (ja) | 口腔貼付剤 | |
| RU2007119721A (ru) | Частицы для лечения легочной инфекции | |
| JP2014521641A5 (enExample) | ||
| JP2023545372A (ja) | デクスメデトミジン塩酸塩を用いた双極性障害及び精神病の治療 | |
| CN1735434A (zh) | 用于预防和治疗伤风与类流感症状的包含精选粘附聚合物的组合物 | |
| JP2016502991A5 (enExample) | ||
| JP2013253038A (ja) | 口腔内溶解型フィルム製剤 | |
| WO2010023874A1 (ja) | ロペラミド塩酸塩含有フィルム製剤 | |
| KR20190009294A (ko) | 비강 울혈을 치료/예방하기 위한 카르복실산 | |
| CN108024952A (zh) | 在治疗发作中用于口颊施用以获得快速起效的咪达唑仑组合物 | |
| CN114585364B (zh) | 谷氨酸2b受体拮抗剂和σ受体激动剂作为止咳药的用途 | |
| JP2007529564A5 (enExample) | ||
| JP2014525891A5 (enExample) | ||
| Rajab et al. | Influence of tamarind seed gum derivatives on the in vitro performance of gastro-retentive tablets based on hydroxypropylmethylcellulose | |
| CN111971034A (zh) | 一种含格隆铵盐的气雾剂药物组合物及其制备方法与应用 | |
| JP2015515971A5 (enExample) | ||
| JP2015533131A5 (enExample) | ||
| JP2012072133A (ja) | 塩酸アンブロキソールの小型徐放性製剤 |